Millennium Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Millennium Management’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-140	Closed	-$1.55K	–	6675
2024 Q1	$1.55K	Sell	140 -241	-63%	-$2.86K	﹤0.01%	6084
2023 Q4	$4.65K	Buy	+381	New	+$8.92K	﹤0.01%	5829
2022 Q3	–	Sell	-10	Closed	-$3K	–	7591
2022 Q2	$3K	Hold	10	–	–	﹤0.01%	6834
2022 Q1	$6K	Sell	10 -52	-84%	-$38.9K	﹤0.01%	6770
2021 Q4	$63K	Buy	62 +3	+5%	+$4.34K	﹤0.01%	6416
2021 Q3	$98K	Sell	59 -6	-9%	-$12.4K	﹤0.01%	6446
2021 Q2	$183K	Buy	+65	New	+$321K	﹤0.01%	6054
2020 Q2	–	Sell	-63	Closed	-$631K	–	4687
2020 Q1	$631K	Buy	+63	New	+$631K	﹤0.01%	2744
2017 Q4	–	Sell	-42	Closed	-$258K	–	4138
2017 Q3	$258K	Buy	+42	New	+$308K	﹤0.01%	3123

Other funds holding ATXI

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Millennium Management's ATXI Position: Q2 2024 in Review

Millennium Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2024, closing a stake of 140 shares — an estimated $1.55K sold.

Millennium Management first reported a position in ATXI in Q3 2017 and held it in 9 quarters. The position peaked at $631K in Q1 2020. 9 funds tracked by Wall St. Rank hold ATXI as of Q2 2024.

Millennium Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Millennium Management sold 140 Avenue Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.55K.
Millennium Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
Millennium Management's Avenue Therapeutics, Inc. Common Stock position peaked at $631K in Q1 2020.
9 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.